The U.S. Food and Drug Administration has recently announced warnings against the use of hydroxychloroquine or chloroquine for treating or preventing SARS beta-coronavirus 19 (COVID-19) infection. Hydroxyquinoline is FDA-approved for the treatment of malaria and some autoimmune conditions but has not been adequately tested or approved for the treatment of COVID-19 and may have very serious adverse effects including QT interval prolongation and ventricular tachycardia. The FDA did issue an Emergency Use Authorization for hydroquinolone in COVID-19 patients who are hospitalized or in clinical trials (where they are continuously monitored) but cautions that outpatients should not be treated or self-medicate with hydroxychloroquine or chloroquine.
>> Read the full FDA Medical Product Safety Information
For more information: